The safety of esophagojejunostomy via a transorally inserted-anvil method vs extracorporeal anastomosis using a circular stapler during total gastrectomy for Siewert type 2 adenocarcinoma of the esophagogastric junction

Xin-Hua Chen†, Yan-Feng Hu†, Jun Luo, Yue-Hong Chen, Hao Liu, Tian Lin, Hao Chen, Guo-Xin Li and Jiang Yu*

Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China

*Corresponding author. Department of General Surgery, Nanfang Hospital, Southern Medical University, No. 1838 North Guangzhou Avenue, Guangzhou, Guangdong 510515, P. R. China. Tel: +86-20-61641681; Fax: +86-20-62787626; Email: balbcyujiang@163.com

†These authors contributed equally to this work.

Abstract

**Background:** Intracorporeal esophagojejunostomy via a transorally inserted-anvil method during laparoscopic total gastrectomy (LTG) for upper gastric cancer has been demonstrated to be feasible, but the use of this assessment exclusively for Siewert type 2 adenocarcinoma of the esophagogastric junction (AEG) has not been reported. **Methods:** A total of 428 consecutive gastric-cancer patients who underwent LTG in Nanfang Hospital from January 2008 to December 2016 were reviewed. Among these patients, 98 were classified as Siewert type 2 AEG. The patients underwent intracorporeal esophagojejunostomy through either a transorally inserted-anvil method (n = 27) or extracorporeal anastomosis using a circular stapler (n = 71). After generating propensity scores with covariates that were associated with developing anastomotic leakage, 26 patients who underwent esophagojejunostomy via the transorally inserted-anvil method (transoral group) were 1:1 matched with 26 patients who underwent the procedure via extracorporeal anastomosis (extracorporeal group). The safety after 30 days post-operatively was compared between the two groups. **Results:** The transoral group and extracorporeal group were balanced regarding the baseline variables. The operative time, reconstruction duration, number of dissected lymph nodes, length of the proximal resection margins, estimated blood loss, intra-operative complication rate, and post-operative recovery course were not significantly different between the two groups. The mean anvil-insertion completion time (9.7 ± 3.0 vs 13.4 ± 2.0 minutes, P < 0.001) and the median incision length (5.5 vs 7.0 cm, P < 0.001) in the transoral group were shorter than those in the extracorporeal group. The incidence of post-operative complications (26.9% vs 23.1%, P = 0.749) and the classification of complication severity (P = 0.939) were similar between the two groups.

Submitted: 30 January 2019; Revised: 8 April 2019; Accepted: 5 May 2019

© The Author(s) 2019. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Conclusions: Intracorporeal esophagojejunostomy through a transorally inserted-anvil method may be a potentially safe approach to simplify and optimize the procedure during LTG for Siewert type 2 AEG.

Key words: adenocarcinoma of the esophagogastric junction; laparoscopic total gastrectomy; esophagojejunostomy; anastomotic leakage

Introduction

Although the incidence of gastric cancer (GC) has declined recently, the proportion of adenocarcinoma of the esophagogastric junction (AEG) has dramatically increased worldwide [1, 2]. Based on the results of the JCOG 9502 trial [3], the abdominal-transhiatal (TH) approach is justified for the treatment of Siewert type 2 AEG. As laparoscopic gastrectomy has been proven to be as safe as open gastrectomy [4–7], the TH approach for AEG is usually performed by laparoscopy.

Conventionally, during laparoscopic total gastrectomy (LTG), esophagojejunostomy is performed through via mini-laparotomy at the upper epigastrum. Nevertheless, due to the limitation of the left inferior phrenic space and the length of the incision, this complicated and challenging procedure becomes more challenging and requires a relatively large incision in order to obtain secure anastomotic procedures, especially for obese patients, thin patients with a high and narrow thoracic oesophagus, or patients who require more extensive resection of the oesophagus [2]. In these situations, the procedure may fail to achieve satisfactory anastomosis and may even easily hurt the liver, spleen, and diaphragm. As a result, some surgeons have turned to thoracotomy, which results in greater trauma accompanied by a higher rate of perioperative morbidity without survival benefits and a loss in the significance of minimally invasive laparoscopy [3, 8, 9]. Thus, many studies of how to perform esophagojejunostomy safely and simply during LTG for upper gastric tumours have been performed [10–15]. However, it is worth noting that the difficulty of LTG for Siewert type 2 AEG is distinguished from that for upper GC because the procedure has to be completed in a high and narrow operation plane.

Excitingly, the transorally inserted-anvil method using OrVil™ can change the orientation of the inserted anvil, simplifying the reconstruction process [16]. Furthermore, when more extensive resection of the oesophagus is required, the transorally inserted-anvil method can reduce the difficulty of esophagojejunostomy and achieve a higher and safer resection margin compared with linear anastomosis [17]. Thus, cases of Siewert type 2 AEG might represent a distinctive treatment indication for the transorally inserted-anvil method. Unfortunately, the exclusive assessment of the procedure for Siewert type 2 AEG has been substantially lacking. In this study, we evaluated the surgical safety and feasibility of intracorporeal esophagojejunostomy through the transorally inserted-anvil method by comparing it with the extracorporeal anastomosis approach during LTG exclusively for Siewert type 2 AEG patients.

Patients and methods

Patients

A total of 428 consecutive GC patients underwent LTG at Nanfang Hospital from January 2008 to December 2016. After two independent surgical oncologists retrospectively reviewed the medical records of these patients, it was determined that 98 patients had Siewert type 2 AEG according to the Siewert classification [18]. These patients underwent intracorporeal oesophagojejunostomy via the transorally inserted-anvil method (n = 27) or extracorporeal anastomosis using a circular stapler (n = 71) depending on the patient’s choice. Before surgery, the patient was presented with a sufficient explanation about the cost and the characteristics of the different reconstruction approaches. There was no difference between the two procedures in terms of the post-operative care. All patients were treated according to the routine post-operative management protocol used in our department. Patients’ demographics, comorbidities, post-operative results, post-operative recovery courses, and pathologic characteristics were retrospectively analysed based on a prospectively maintained database [19].

After generating propensity score matching (PSM) with six covariates (sex, age, body mass index [BMI], neoadjuvant chemotherapy, combined organ(s) resection, and the number of dissected lymph nodes), 26 Siewert type 2 AEG patients who underwent intracorporeal esophagojejunostomy via the transorally inserted-anvil method (transoral group) and 26 patients who underwent the extracorporeal anastomosis approach (extracorporeal group) were matched with a 1:1 ratio (Figure 1). The post-operative recovery course and safety after 30 days post-operatively were then compared between the two groups. All the Siewert type 2 AEG patients in this trial had stomach-predominant cancer [20] and their staging was determined according to the 7th UICC. This study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University.

Surgical procedures

Each patient was placed in the supine position with the legs oriented slightly apart (relaxed dorsal lithotomy position). Dissection of the regional lymph nodes and resection of the stomach were performed as described in our previous study for both approaches [21]. Total gastrectomy with D2 or D2 + No. 10 lymphadenectomy was performed in all patients. Either spleenectomy or pancreas- and spleen-preserving splenic hilar lymph-node dissection was conducted to dissect the No. 10 lymph node. The latter was performed as we reported previously [22]. Then, the duodenal bulb was transected using a linear stapler, followed by the transection of the distal oesophagus a proper distance away from the margin of the tumour with the linear stapler.

Transorally inserted-anvil method

After completing the lymph-node dissection, the OrVil™ anvil was inserted transorally by anaesthetists until the tip of the transoral tube reached the position to be transected (Figure 2A and B). After the transection of the distal oesophagus (Figure 2C), the entire specimen was removed and placed into a specimen-collection bag. Concurrently, a small cavity was made on the left edge of the staple line in the oesophageal stump with a harmonic scalpel. Then, the anvil was dragged from the hole using a laparoscopic grasper until the centre rod...
of the anvil came into view (Figure 2D). After that, the thread connecting the transoral tube and the anvil was cut for release (Figure 2E); then, the tube was removed from the abdominal cavity through one trocar hole. At this point, the insertion of the anvil was complete (Figure 2F).

Later, the left upper port site was extended to 4–6 cm in length, through which the specimen-collection bag was removed. The jejunum was transected 15 cm away from the Treitz ligament with the linear stapler, and a side-to-side jejunoojejunostomy was then performed with the linear stapler (Figure 3A). The circular stapler was inserted into a surgical glove for subsequent pneumoperitoneum re-establishment (Figure 3B). After that, the circular stapler was positioned within the jejunal limb through the distal jejunal stump. Both jejunal loops on the stapler shaft and the centre rod were anchored with a rubber band to create a special slippage for preventing their separation and tearing the embedded tissues (Figure 3C). Then, the stapler shaft, a surgical glove, and a wound protector were connected as a single-site access system to re-establish the pneumoperitoneum (Figure 3D) and to complete the subsequent intracorporeal oesophagojejunal anastomosis.

In the laparoscopic view, the circular stapler and the anvil were linked and then fired to complete the anastomosis (Figure 4A). After that, the rubber band was cut off and removed (Figure 4B). The circular stapler was then removed and the incisal margin was checked (Figure 4C). Then, the jejunal stump was closed using the linear stapler (Figure 4D). Last but not least, we assessed the anastomosis by laparoscopy combined with on-table endoscopy (Figure 5).

**Extracorporeal anastomosis using the circular stapler**

The completion of regional lymph-node dissection was followed by making a small midline incision of 8–10 cm at the epigastrium. Before transecting the distal oesophagus, the purse-string forceps were prepositioned and the suturing was completed. After transecting the distal oesophagus, the anvil was inserted into the proximal oesophagus and the purse-string suture was tightened to represent the anastomosis end of the oesophagus. The specimen was removed via mini-laparotomy. Then, extracorporeal esophagojejunalostomy was performed with the circular stapler.

**Outcomes**

The primary outcomes were the rate of early post-operative complications and the anastomotic leakage (AL). Early post-operative complications were assessed within 30 days after the surgery and scaled according to the Clavien–Dindo Classification and Accordion Classification [23], which mainly includes anastomotic complications (leakage, bleeding, and stenosis), intra-abdominal infections, intra-abdominal bleeding, intestinal obstructions, pancreatic fistula, pancreatitis, and wound infections, as well as systemic complications (pulmonary, urinary, renal, hepatic, cardiac, and endocrine). AL was
defined as ‘a complete intestinal wall defect at the anastomotic suture line detected with a radiologic contrast medium study or positive color test’ [24]. In our centre, the cases were all confirmed with the methylene blue test and a radiology study with a water-soluble contrast medium and/or endoscopy.

The secondary outcomes were intra-operative complications (any complications that occurred intra-operatively), surgical outcomes (number of dissected lymph nodes, combined organ(s) resection, total operative duration, anvil-insertion duration, reconstruction duration, estimated blood loss, incision length, and length of proximal resection margins) and post-operative recovery (time to first ambulation, time to first flatus, time to first liquid resumption, time to first liquid diet, time to first soft diet, and post-operative hospital stay).

Statistical analysis

The data were analysed using the SPSS statistical software program (SPSS 22.0). Six covariates (sex, age, BMI, neoadjuvant chemotherapy history, combined organ(s) resection and the number of dissected lymph nodes) were selected to perform PSM. A propensity score was calculated using a logistic-regression model and a nearest-neighbour-matching algorithm. After PSM, the transoral group was 1:1 matched with the extracorporeal group. Data are presented as the mean ± standard deviation for continuous variables (for those with non-normal distributions, medians and ranges are shown) and as numbers (%) for categorical variables. Student t-test or the Mann–Whitney U test was used to compare the baseline characteristics and short-term outcomes for continuous variables, while, for categorical variables, the chi-square test or Fisher’s exact test was used. A P<0.05 was considered statistically significant.

Results

Patient characteristics

After PSM, no significant difference was found in age, sex, BMI, neoadjuvant chemotherapy, combined organ(s) resection, or the number of dissected lymph nodes. Both groups were balanced regarding the baseline variables (Table 1).

Surgical outcomes

The total operative time and duration of reconstruction were not significantly different between the two groups (both P>0.05), whereas the anvil-insertion completion time was
shorter in the transoral group than in the extracorporeal group (9.7 ± 3.0 vs 13.4 ± 2.12 minutes, *P* < 0.001). The median length of the incision was shorter in the transoral group than in the extracorporeal group (5.5 vs 7.0 cm, *P* < 0.001). The length of the proximal resection margins, estimated blood loss, number of retrieved lymph nodes, intra-operative complication rate, and post-operative recovery course (including the time to first ambulation, flatus, liquid resumption, liquid diet, soft diet, and post-operative hospital stay) showed no significant difference (Table 2).

**Intra-operative and post-operative complications**

The intra-operative complications, including spleen injury and vessel bleeding, were similar between the two groups (11.5% vs
The incidence of post-operative complications (26.9% vs 23.1%, \( P = 0.749 \)) and the classification of complication severity (\( P = 0.939 \)) were approximately the same. Notably, the rates of anastomotic complications and anastomotic bleeding seemed to be lower in the transoral group than those in the extracorporeal group, but the difference was not significant (11.5% vs 19.2%, \( P = 0.702 \) and 0.0% vs 7.7%, \( P = 0.471 \), respectively). AL was 11.5% in both groups and one of the cases of AL also

**Table 1.** Comparisons of baseline characteristics between the two groups.

| Variable                        | Transoral group (n = 26) | Extracorporeal group (n = 26) | P-value |
|---------------------------------|--------------------------|-------------------------------|---------|
| Age, years                      | 61.8 ± 9.1               | 61.3 ± 7.9                    | 0.834   |
| Gender                          |                          |                               | 1.000   |
| Male                            | 22 (84.6)                | 21 (80.8)                     |         |
| Female                          | 4 (15.4)                 | 5 (19.2)                      |         |
| Body mass index, kg/m²          | 22.5 ± 3.4               | 21.6 ± 3.3                    | 0.353   |
| Hemoglobin, g/L                 | 103.2 ± 35.3             | 108.4 ± 36.4                  | 0.610   |
| Albumin, g/L                    | 37.0 ± 4.0               | 38.7 ± 3.8                    | 0.145   |
| ECOG score, n (%)               |                          |                               | 0.272   |
| 0                               | 13 (50.0)                | 15 (57.7)                     |         |
| 1                               | 7 (26.9)                 | 10 (38.5)                     |         |
| 2                               | 3 (11.5)                 | 1 (3.8)                       |         |
| 3                               | 3 (11.5)                 | 0 (0.0)                       |         |
| Comorbidities                   |                          |                               |         |
| Hypertension                    | 5 (19.2)                 | 4 (15.4)                      | 1.000   |
| Diabetes mellitus               | 2 (7.7)                  | 3 (11.5)                      | 1.000   |
| Cardiovascular disease          | 0 (0.0)                  | 2 (7.7)                       | 0.471   |
| Pulmonary disease               | 2 (7.7)                  | 1 (3.8)                       | 1.000   |
| Hepatic disease                 | 1 (3.8)                  | 5 (19.2)                      | 0.193   |
| History of abdominal surgery    | 0 (0.0)                  | 2 (7.7)                       | 0.671   |
| Neoadjuvant chemotherapy        | 2 (7.7)                  | 5 (19.2)                      | 0.416   |
| Tumour diameter, cm             | 46.0 ± 14.1              | 47.1 ± 14.1                   | 0.791   |
| TMN stage                       |                          |                               | 0.569   |
| I                               | 0 (0.0)                  | 1 (3.8)                       |         |
| II                              | 7 (26.9)                 | 10 (38.5)                     |         |
| III                             | 19 (73.1)                | 12 (46.2)                     |         |
| IV                              | 0 (0.0)                  | 3 (11.5)                      |         |

Values presented with mean ± standard deviation or n (%). ECOG, Eastern Cooperative Oncology Group.
demonstrated anastomotic bleeding in the extracorporeal group. Two-thirds of the patients with AL required a second operation in both groups. In addition, the rate of pancreatic fistula was 3.85% in both groups (Table 3).

The most common post-operative complication was pneumonia in both groups (23.1% vs 19.2%, \( P = 1.000 \)). In the transoral group, three out of six cases of pneumonia followed AL and/or pancreatic fistula, while, in the extracorporeal group, all five cases of pneumonia were accompanied by anastomotic complications and/or pancreatic fistula. In addition, there was no significant difference between the two groups regarding intra-abdominal infection (\( P = 1.000 \)), ileus (\( P = 0.234 \)), mediastinal infection (\( P = 1.000 \)), wound infection (\( P = 1.000 \)), or liver dysfunction (\( P = 1.000 \)). In addition, all these post-operative complications were mainly attributed to the occurrence of AL and pancreatic fistula, except for three cases of pneumonia in the transoral group and one case of liver dysfunction in the extracorporeal group.

**Discussion**

Esophagojejunostomy during LTG for Siewert type 2 AEG remains a challenge and more studies are needed to explore an optimal method. Based on the results of the trials concerning the feasibility of esophagojejunostomy during LTG for upper gastric tumours, the transorally inserted-anvil method has the advantage of changing the direction of anvil insertion, simplifying the reconstruction process and decreasing the duration of esophagojejunostomy [25–29]. Thus, in this trial, we aimed to evaluate the surgical safety and feasibility of intracorporeal esophagojejunostomy through the transorally inserted-anvil method during LTG for Siewert type 2 AEG.

| Variable                        | Transoral group (n = 26) | Extracorporeal group (n = 26) | P-value |
|--------------------------------|--------------------------|-------------------------------|---------|
| Number of dissected lymph nodes| 40.1 ± 18.3              | 30.8 ± 18.8                   | 0.163   |
| Combined organ(s) resection     | 1 (3.8)                  | 3 (11.5)                      | 0.603   |
| Total operative duration, minutes | 234.8 ± 33.9           | 227.4 ± 38.1                 | 0.457   |
| Anvil insertion*                | 9.7 ± 3.0                | 13.4 ± 2.2                    | <0.001  |
| Reconstruction                  | 48.4 ± 12.6              | 53.9 ± 8.3                    | 0.067   |
| Estimated blood loss, mL        | 124.2 ± 115.4            | 143.5 ± 130.6                 | 0.576   |
| Incision length, cm             | 5.5 [1.0]                | 7.0 [2.0]                     | <0.001  |
| Length of proximal resection margins, mm | 25.4 ± 16.2     | 27.3 ± 15.5                   | 0.666   |
| Time to first ambulation, days  | 3.6 ± 3.9                | 4.9 ± 5.9                     | 0.348   |
| Time to first flatus, days      | 3.0 [1.0]                | 3.0 [1.0]                     | 0.116   |
| Time to first liquid resumption, days | 3.2 ± 1.2             | 4.7 ± 3.9                     | 0.075   |
| Time to first liquid diet, days | 4.4 ± 1.3                | 5.9 ± 4.1                     | 0.086   |
| Time to first soft diet, days   | 6.2 ± 2.0                | 7.6 ± 4.6                     | 0.170   |
| Post-operative hospital stay, days | 14.4 ± 18.4            | 16.2 ± 20.3                   | 0.743   |

Values presented with mean ± standard deviation, median [interquartile range], or n (%).

*Anvil-insertion time in the transoral group: from transection of the oesophagus to disconnection of the thread linking the transoral tube and the anvil; anvil-insertion time in the extracorporeal group: from preposition of the purse-string forceps to completion of anvil fixation.

| Variable                        | Transoral group (n = 26) | Extracorporeal group (n = 26) | P-value |
|--------------------------------|--------------------------|-------------------------------|---------|
| Intra-operative complications, n (%) | 3 (11.5)              | 2 (7.7)                       | 1.000   |
| Spleen injury                   | 2 (7.7)                  | 1 (3.8)                       | 1.000   |
| Vessel bleeding                 | 1 (3.8)                  | 1 (3.8)                       | 1.000   |
| Post-operative complications, n (%) | 7 (26.9)              | 6 (23.1)                      | 0.749   |
| Anastomotic complications       | 3 (11.5)                 | 4 (15.4)                      | 1.000   |
| Anastomotic leakage             | 3 (11.5)                 | 3 (11.5)                      | 1.000   |
| Anastomotic bleeding            | 0 (0.0)                  | 2 (7.7)                       | 0.471   |
| Intra-abdominal infection       | 2 (7.7)                  | 3 (11.5)                      | 1.000   |
| Mediastinal infection           | 0 (0.0)                  | 1 (3.8)                       | 1.000   |
| Ileus                           | 0 (0.0)                  | 3 (11.5)                      | 0.234   |
| Wound infection                 | 0 (0.0)                  | 1 (3.8)                       | 1.000   |
| Pneumonia                       | 6 (23.1)                 | 5 (19.2)                      | 1.000   |
| Pancreatic fistula              | 1 (3.8)                  | 1 (3.8)                       | 1.000   |
| Liver dysfunction               | 0 (0.0)                  | 1 (3.8)                       | 1.000   |
| Complication classification*, n (%) | 0.939                   |                               |         |
| I                               | 0 (0.0)                  | 1 (3.8)                       |         |
| II                              | 4 (15.4)                 | 2 (7.7)                       |         |
| IIIa                            | 1 (3.8)                  | 1 (3.8)                       |         |
| IV                              | 2 (7.7)                  | 2 (7.7)                       |         |
| Second operation, n (%)         | 2 (7.7)                  | 2 (7.7)                       | 1.000   |

*According to the Clavien–Dindo classification.
Reviewing the trials concerning the feasibility of the transorally inserted-anvil method for esophagojunostomy during LTG for upper gastric tumours, we found some limitations and learned from them to obtain comparable and reliable evidence. Most of the previous studies focused on introducing their experience with a few cases [30–32]. Some were significantly heterogeneous in terms of the number of cases included. A study conducted by Chong-Wei et al. [33] enrolled patients whose primary diseases differed from Zollinger–Ellison syndrome, and included a variety of diseases ranging from stromal tumours in the cardia to adenocarcinoma in the stomach. The patients included in a study carried out by Marangoni et al. [25] underwent different surgeries, including laparoscopic Ivor–Lewis esophagectomy, total gastrectomy, and subtotal gastrectomy. Choi et al. [34] studied the incidence rate of AL and stricture of esophagojunostomy with the transorally inserted-anvil method. However, the operative approaches in the study included open (51.7%), laparoscopic (43.3%), and robotic (5.0%) approaches, and the range of gastric resection approaches included total gastrectomy (81.7%), proximal gastrectomy (10.0%), and completion gastrectomy (8.3%). Jung et al. [28] compared the safety of intracorporeal circular stapling esophagojunostomy via the transorally inserted-anvil method with the extracorporeal anastomosis approach. The time period in the transoral group was from 2005 to 2014, while that in the extracorporeal group was between 2004 and 2008. As far as we know, the treatment types and nursing methods used for GC differ in these two separate periods. Shida et al. [27] assessed the usefulness and safety of esophagojunostomy through the transorally inserted-anvil method by analysing GC patients with tumour locations in the upper third, middle third, upper to middle, and lower to upper regions, and the surgeries included both LTG and open total gastrectomy. Few previous studies have investigated the feasibility and advantages of esophagojunostomy with the transorally inserted-anvil method during LTG, focusing exclusively on Siewert type 2 AEG patients.

Moreover, some related studies have compared the transorally inserted-anvil method with another anastomosis approach with selection bias and differences in baseline characteristics [28–29]. These limitations may impair the objectivity of the results. PSM was conducted to compensate for selection bias and to avoid potential confounding effects. Thus, in this study, we chose consecutive Siewert type 2 AEG patients in the same period and performed a PSM analysis to further balance the factors that may affect the assessment of the safety of anastomosis, not only the baseline variables that were unbalanced between the two groups. The risk factors for the development of AL in patients undergoing LTG according to the data of our centre include sex, age, neoadjuvant chemotherapy, combined organ(s) resection, and invasion of the oesophagus [35]. After PSM, the baseline and treatment-related characteristics were balanced and patients were 1:1 matched between the two approaches.

Insecure anastomosis may cause severe complications, especially AL, which will prolong the post-operative hospital stay, increase medical costs, and even affect long-term prognosis [36, 37]. According to the nationwide internet-based database of Japan, the incidence of AL after total gastrectomy was 4.4% (881/20011) in 2011 [38]. The systematic analysis reported a similar incidence of 2.45% [39]. Therefore, AL was regarded as one of the most critical post-operative complications clinically and the incidence of AL has been deemed one of the key quality indicators to investigate the safety of esophagojunostomy approaches after total gastrectomy in this study. In the present study, the incidence rate of AL reached 11.5%, which is quite high compared with previous reports about the safety of the transorally inserted-anvil method for esophagojunostomy during LTG. However, in fact, the data for our centre indicated that the incidence rate of AL after total gastrectomy was 2.3% (12/525) from January 2008 to December 2016. The difference occurred because the factors used to perform PSM were risk factors for the development of AL according to the data in our centre [39]. Additionally, these factors in both groups after PSM were at a high level. Among the six Siewert type 2 AEG patients with AL, all were male with a mean age of 65.5 years, two received neoadjuvant chemotherapy, and one received chemotherapy combined with organ resection. Thus, the high incidence rate of AL in the Siewert type 2 AEG patients in this study was reasonable.

Interestingly, contrary to the results reported by Kawamura et al. [40], which showed that the esophagojunostomy procedure via the transorally inserted-anvil method was an independent risk factor for anastomotic complications during LTG, our finding indicated that esophagojunostomy via the transorally inserted-anvil method during LTG for Siewert type 2 AEG patients achieved a lower risk of anastomotic complications, although the difference was not significant. Furthermore, the transorally inserted-anvil method can simplify the esophagojunostomy procedure and take advantage of the duration of anvil insertion and the mean length of incision without impairing its safety. The development of LTG has been limited mainly because of the difficulty of reconstruction of the digestive tract, especially with esophagojunostomy, which is seen as the most complicated and difficult part of the procedure even by experienced surgeons. Hence, the short time of anvil insertion and small incision reflect the simplification and optimization of the surgical procedure to a large extent. Therefore, explorations of how to perform esophagojunostomy safely and simply during LTG in Siewert type 2 AEG patients should take into account the transorally inserted-anvil method.

The limitations of our study are also apparent. Although the data in our study were prospectively collected, our study was retrospectively analysed and the inherent selection bias was adjusted but not completely eliminated by using PSM. Furthermore, since the cardinal number of Siewert type 2 AEG patients was limited, the number of samples in the analysis was small, which may have impaired the power of the test. In addition, the fact that esophagojunostomy with the extracorporeal anastomosis approach is conventional and performed proficiently in our centre may weaken the advantage of the transorally inserted-anvil method in the study. Last but not least, because the follow-up was routinely conducted and included a complete detailed assessment of the anastomotic stoma 1 month after surgery, the recording of anastomotic stenosis was not complete and the occurrence of anastomotic stenosis might have been lower than the actual condition. As a result, we abandoned the analysis of anastomotic stenosis. Thus, the assessment of anastomotic stenosis needs to be prospectively investigated in a well-designed randomized trial.

In conclusion, intracorporeal esophagojunostomy via a transorally inserted-anvil method may be a potentially safe approach to simplify and optimize the esophagojunostomy procedure during LTG in Siewert type 2 AEG patients.

**Funding**

This work was supported by Medtronic, National Key Clinical Specialities Construction Program of China [No. [2012]121], Science and Technology Planning Project of Guangdong Province [2013B021800313], and Special Funds
for the Cultivation of Guangdong College Students’ Scientific and Technological Innovation [pdjha0094].

Authors’ contributions

Study conception and design: G.X.L., J.Y. Acquisition of data: X.H.C., Y.F.H., J.L., Y.H.C., H.L., T.L., H.C. Data analysis and interpretation: X.H.C., Y.F.H., J.L., Y.H.C., H.L., T.L., H.C. Drafting of manuscript: X.C., Y.F.H. Critical revision: G.X.L., J.Y. All authors read and approved the final version.

Acknowledgements

We are grateful to the documenters in Nanfang Hospital for data collection and to members of the Chinese Laparoscopic Gastrointestinal Surgery Study Group for support.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

1. Kusano C, Gotoda T, Khor CJ et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol 2008;23:1662–5.
2. Blot WJ, Devesa SS, Kneller RW et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265:1287–9.
3. Sasako M, Sano T, Yamamoto S et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006;7:644–51.
4. Hu Y, Huang C, Sun Y et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol 2016;34:1350–7.
5. Etoh T, Honda M, Kumamaru H et al. Morbidity and mortality from a propensity score-matched, prospective cohort study of laparoscopic versus open total gastrectomy for gastric cancer: data from a nationwide web-based database. Surg Endosc 2018;32:2766–73.
6. Hyung WJ, Yang HK, Han SU et al. A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi-center phase II clinical trial. KLAS 03. Gastric Cancer 2019;22:214–22.
7. Huang CM, Lv CB, Lin JX et al. Laparoscopic-assisted versus open total gastrectomy for Siewert type II and III esophagogastric junction carcinoma: a propensity score-matched case-control study. Surg Endosc 2017;31:3495–503.
8. Omlooj JM, Lagarde SM, Hulscher JB et al. Extended transthoracic resection compared with limited transthiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246:992–1001.
9. Hulscher JB, Tijsjes JG, Obertop H et al. Transthoracic versus transthiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001;72:306–13.
10. Okabe H, Satoh S, Inoue H et al. Esophagojejunostomy through minilaparotomy after laparoscopic total gastrectomy. Gastric Cancer 2007;10:176–80.
11. Chen S, Chen XJ, Chen DW et al. A novel anti-reflux reconstruction after laparoscopic total gastrectomy: jejunal pouch-esophageal anti-reflux anastomosis. Gastroenterol Rep (Oxf) 2018;6:234–8.
12. Uyama I, Sugioka A, Fujita J et al. Laparoscopic total gastrectomy with distal pancreatectomy and D2 lymphadenectomy for advanced gastric cancer. Gastric Cancer 1999;2:230–4.
13. Inaba K, Satoh S, Ishida Y et al. Overlap method: novel intracorporeal esophagojejunostomy after laparoscopic total gastrectomy. J Am Coll Surg 2010;211:e25–9.
14. Nunobe S, Hiki N, Tanimura S et al. Three-step esophagojejunal anastomosis with atraumatic anvil insertion technique after laparoscopic total gastrectomy. J Gastrointest Surg 2011; 15:1520–5.
15. Chaiyasate K, Jacobs M, Brooks SE et al. The uncut Roux-en-Y jejunal pouch: a new reconstruction technique for total gastrectomy. Surgery 2007;142:33–9.
16. Jeong O, Park YK. Intracorporeal circular stapling esophagojejunostomy using the transorally inserted anvil (OrVil) after laparoscopic total gastrectomy. Surg Endosc 2009;23:2624–30.
17. Yao ZD, Yang H, Cui M et al. Application of transorally inserted anvil (OrVil(TM)) in laparoscopic-assisted radical resection for Siewert type II adenocarcinoma of the esophagogastric junction. Zhonghua Wei Chang Wai Ke Za Zhi 2013;16:345–9.
18. Marc R, Cheng KK. Classification of adenocarcinoma of the esophagogastric junction. Br J Surg 1999;86:1098–9.
19. Hu YF, Yu J, Zhang C et al. Development and implementation of a clinical data mining system for gastric cancer surgery. Zhonghua Wei Chang Wai Ke Za Zhi 2010;13:510–5.
20. Yamashita H, Seto Y, Sano T et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer 2017;20:69–83.
21. Mou TY, Hu YF, Yu J et al. Laparoscopic splenic hilum lymph node dissection for advanced proximal gastric cancer: a modified approach for pancreas- and spleen-preserving total gastrectomy. World J Gastroenterol 2013;19:4992–9.
22. Zheng L, Zhang C, Wang D et al. Laparoscopic spleen-preserving hilar lymph node dissection through pre-pancreatic and retro-pancreatic approach in patients with gastric cancer. Cancer Cell Int 2016;16:52.
23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–13.
24. Schardey HM, Joosten U, Finke U et al. The prevention of anastomotic leakage after total gastrectomy with local decontamination: a prospective, randomized, double-blind, placebo-controlled multicenter trial. Ann Surg 1997;225:172–80.
25. Marangoni G, Villa F, Shamil E et al. OrVil-assisted anastomosis in laparoscopic upper gastrointestinal surgery: friend of the laparoscopic surgeon. Surg Endosc 2012;26:811–7.
26. Jung YJ, Kim DJ, Lee JH et al. Safety of intracorporeal circular stapling esophagojejunostomy using trans-orally inserted anvil (OrVil) following laparoscopic total or proximal gastrectomy—comparison with extracorporeal anastomosis. World J Surg Oncol 2013;11:209.
27. Shida A, Mitsumori N, Fujioka S et al. Comparison of short-term and long-term clinical outcomes between laparoscopic and open total gastrectomy for patients with gastric cancer. Surg Laparosc Endosc Percutan Tech 2016;26:319–23.
28. Sakuramoto S, Kikuchi S, Futawatari N et al. Technique of esophagojejunostomy using transoral placement of the pre-tilted anvil head after laparoscopic gastrectomy for gastric cancer. Surgery 2010;147:742–7.
29. Kunisaki C, Makino H, Oshima T et al. Application of the transorally inserted anvil (OrVil) after laparoscopy-assisted total gastrectomy. Surg Endosc 2011;25:1300–5.
30. Hu YF, Wang D, Lin T et al. An automatically contamination-avoiding technique for intracorporeal esophagojejunostomy using a transorally inserted anvil during laparoscopic total gastrectomy for gastric cancer. World J Surg Oncol 2015;13:154.
31. Smolarek S, Salih A, Kazanowski M et al. Laparoscopic assisted total gastrectomy for gastric cancer—operative technique. Wideochir Inne Tech Maloinwazyjne 2015;10:133–7.
32. Li X, Ke C. Recent advances of anastomosis techniques of esophagojejunostomy after laparoscopic totally gastrectomy in gastric tumor. Zhonghua Wei Chang Wai Ke Za Zhi 2015;18:512–5.
33. Chong-Wei K, Dan-Lei C, Dan D. A modified technique for esophagojejunostomy or esophagogastrostomy after laparoscopic gastrectomy. Surg Laparosc Endosc Percutan Tech 2013;23:e109–15.
34. Choi AH, Arrington A, Falor A et al. Assessment of the double-staple technique for esophagoenteric anastomosis in gastric cancer. J Gastrointest Surg 2016;20:688–92.
35. Luo J, Chen X, Chen YH et al. Analysis of risk factors and intervention measures of esophagojejunal anastomotic leakage in gastric cancer patients after laparoscopic total gastrectomy. Chin J Pract Surg 2019;39:168–72.
36. Oh SJ, Choi WB, Song J et al. Complications requiring reoperation after gastrectomy for gastric cancer: 17 years experience in a single institute. J Gastrointest Surg 2009;13:239–45.
37. Tu RH, Lin JX, Zheng CH et al. Development of a nomogram for predicting the risk of anastomotic leakage after a gastrectomy for gastric cancer. Eur J Surg Oncol 2017;43:485–92.
38. Watanabe M, Miyata H, Gotoh M et al. Total gastrectomy risk model: data from 20,011 Japanese patients in a nationwide internet-based database. Ann Surg 2014;260:1034–9.
39. Inokuchi M, Otsuki S, Fujimori Y et al. Systematic review of anastomotic complications of esophagojejunostomy after laparoscopic total gastrectomy. World J Gastroenterol 2015;21:9656–65.
40. Kawamura H, Ohno Y, Ichikawa N et al. Anastomotic complications after laparoscopic total gastrectomy with esophagojejunostomy constructed by circular stapler (OrVil™) versus linear stapler (overlap method). Surg Endosc 2017;31:5175–82.